Dr. Hensin Tsao, shares his insight on why skin cancer cases are increasing, how new immunotherapy treatments bring hope and why dermatologists should be on the look out for new challenges.
Melanoma patients with fewer than 50 nevi may develop more aggressive melanomas than those with greater than 50 nevi, underscoring the need for education and consideration for skin cancer screening in all patients based on their overall risk.
Concerns have been raised over an FDA Drug Safety Communication about spontaneously submitted adverse reactions in patients using this topical treatment for actinic keratosis as well as labeling changes that were implemented because of those reports. One expert offers perspective.
The medical landscape has changed dramatically for advanced melanoma since 2011, with both individual and combination therapy regimens gaining approval in even recent months. While modern genomics knowledge and knowledge of the immune system have brought about significant improvements in response and longer survival periods for some patients, there is still no cure.